Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at DNA vaccine therapy after bone marrow transplant for myeloma (Educated donor lymphocytes, EDL)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at DNA vaccine therapy to help treat people with myeloma after a bone marrow transplant.
Myeloma is a type of cancer that develops from cells in the bone marrow called plasma cells. Most patients will have chemotherapy for myeloma and this can get the cancer under control (
Some patients have a bone marrow transplant. The bone marrow is donated by a matched donor (usually a sister or brother), to try to cure the cancer. But even a transplant may not work in all patients and sometimes the cancer may come back. If this happens, the patient may have a drip of white blood cells called
This trial looked into using a DNA vaccine which is made from a sample of the patient’s cancer. The donor had this vaccine before their lymphocytes were collected. The doctors hoped giving this vaccine to the donor would ‘educate’ their lymphocytes. When the donor’s lymphocytes were given to the patient, the patient’s immune system would be more able to recognise the cancer cells and kill them. The aims of this trial were to find out if
- It is possible to make the DNA vaccine and to vaccinate donors
- The patient’s immune system can recognise and kill the cancer cells
Summary of results
This trial was never finished and so there are no results available. The researchers were unable to recruit enough patients.
How to join a clinical trial
Prof C. Ottensmeier
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Tenovus Research Laboratory